Nothing Special   »   [go: up one dir, main page]

Lazzaro et al., 2000 - Google Patents

Induction of differentiation by 1α-hydroxyvitamin D5 in T47D human breast cancer cells and its interaction with vitamin D receptors

Lazzaro et al., 2000

Document ID
9825840910441871526
Author
Lazzaro G
Agadir A
Qing W
Poria M
Mehta R
Moriarty R
Gupta T
Zhang X
Mehta R
Publication year
Publication venue
European Journal of Cancer

External Links

Snippet

The role of the active metabolite of vitamin D, 1, 25 dihydroxyvitamin D3 (1, 25 (OH) 2D3), in cell differentiation is well established. However, its use as a differentiating agent in a clinical setting is precluded due to its hypercalcaemic activity. Recently, we synthesised a relatively …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Similar Documents

Publication Publication Date Title
Lazzaro et al. Induction of differentiation by 1α-hydroxyvitamin D5 in T47D human breast cancer cells and its interaction with vitamin D receptors
James et al. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells
Cross et al. 25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis
Slominski et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management
Feldman et al. Vitamin D and prostate cancer
Liel et al. Estrogen increases 1, 25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa
Polek et al. Vitamin D and prostate cancer
Mehta et al. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1α-hydroxyvitamin D 5
Lou et al. 25‐Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells
Narvaez et al. Functions of 1α, 25-dihydroxyvitamin D3 in mammary gland: from normal development to breast cancer
Lopes et al. Vitamin D and the mammary gland: a review on its role in normal development and breast cancer
Krishnan et al. The role of vitamin D in prostate cancer
Narvaez et al. Characterization of a vitamin D3-resistant MCF-7 cell line
Peehl et al. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer
Lee et al. Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer
You et al. RRR-α-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation
Welsh Vitamin D and prevention of breast cancer 1
Li et al. Tumoral vitamin D synthesis by CYP27B1 1-α-hydroxylase delays mammary tumor progression in the PyMT-MMTV mouse model and its action involves NF-κB modulation
Narvaez et al. Differential effects of 1, 25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant
Wu et al. 1α, 25-Dihydroxyvitamin D3 antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21waf1 upregulation in human osteosarcoma
Baurska et al. Structure–function analysis of vitamin D2 analogs as potential inducers of leukemia differentiation and inhibitors of prostate cancer proliferation
Kittaka et al. Potent 19-norvitamin D analogs for prostate and liver cancer therapy
Zhang et al. Vitamin D receptor is a novel drug target for ovarian cancer treatment
Reichrath et al. Immunohistochemical analysis of 1, 25-dihydroxyvitamin D 3 receptor in cervical carcinoma
Vivanco et al. A transition in transcriptional activation by the glucocorticoid and retinoic acid receptors at the tumor stage of dermal fibrosarcoma development.